newsfilter
← Latest News
GlobeNewswire·

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune